Header Logo

Connection

John Zajecka to Female

Back to Details
This is a "connection" page, showing publications John Zajecka has written about Female.
John Zajecka
Connection Strength
0.514
Female
  1. A 5-Year Observational Study of Patients With Treatment-Resistant Depression Treated With Vagus Nerve Stimulation or Treatment as Usual: Comparison of Response, Remission, and Suicidality. Am J Psychiatry. 2017 07 01; 174(7):640-648.
    View in: PubMed
    Score: 0.042
  2. Long-term efficacy, safety, and tolerability of L-methylfolate calcium 15 mg as adjunctive therapy with selective serotonin reuptake inhibitors: a 12-month, open-label study following a placebo-controlled acute study. J Clin Psychiatry. 2016 May; 77(5):654-60.
    View in: PubMed
    Score: 0.040
  3. Efficacy and safety of agomelatine in the treatment of major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled trial. J Clin Psychopharmacol. 2010 Apr; 30(2):135-44.
    View in: PubMed
    Score: 0.026
  4. Oral divalproex sodium loading for adolescent outpatients with acute mania/hypomania: a report of 2 cases. J Clin Psychiatry. 2008 Jun; 69(6):1016-8.
    View in: PubMed
    Score: 0.023
  5. A comparison of the efficacy, safety, and tolerability of divalproex sodium and olanzapine in the treatment of bipolar disorder. J Clin Psychiatry. 2002 Dec; 63(12):1148-55.
    View in: PubMed
    Score: 0.016
  6. Sexual function and satisfaction in the treatment of chronic major depression with nefazodone, psychotherapy, and their combination. J Clin Psychiatry. 2002 Aug; 63(8):709-16.
    View in: PubMed
    Score: 0.015
  7. Strategies for the treatment of antidepressant-related sexual dysfunction. J Clin Psychiatry. 2001; 62 Suppl 3:35-43.
    View in: PubMed
    Score: 0.014
  8. Development and validation of a screening instrument for bipolar spectrum disorder: the Mood Disorder Questionnaire. Am J Psychiatry. 2000 Nov; 157(11):1873-5.
    View in: PubMed
    Score: 0.014
  9. A comparison of nefazodone, the cognitive behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic depression. N Engl J Med. 2000 May 18; 342(20):1462-70.
    View in: PubMed
    Score: 0.013
  10. Construct validity of life chart functioning scales for use in naturalistic studies of bipolar disorder. J Psychiatr Res. 2000 May-Jun; 34(3):187-92.
    View in: PubMed
    Score: 0.013
  11. Prevention of Recurrence After Recovery From a Major Depressive Episode With Antidepressant Medication Alone or in Combination With Cognitive Behavioral Therapy: Phase 2 of a 2-Phase Randomized Clinical Trial. JAMA Psychiatry. 2020 03 01; 77(3):237-245.
    View in: PubMed
    Score: 0.013
  12. Double-blind, placebo-controlled, proof-of-concept trial of a kappa-selective opioid receptor antagonist augmentation in treatment-resistant depression. Ann Clin Psychiatry. 2020 02; 32(4):18-26.
    View in: PubMed
    Score: 0.013
  13. Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression: A Randomized Clinical Trial. JAMA Psychiatry. 2019 09 01; 76(9):893-903.
    View in: PubMed
    Score: 0.013
  14. Safety of abrupt discontinuation of fluoxetine: a randomized, placebo-controlled study. J Clin Psychopharmacol. 1998 Jun; 18(3):193-7.
    View in: PubMed
    Score: 0.012
  15. Discontinuation symptoms after treatment with serotonin reuptake inhibitors: a literature review. J Clin Psychiatry. 1997 Jul; 58(7):291-7.
    View in: PubMed
    Score: 0.011
  16. Importance of establishing the diagnosis of persistent anxiety. J Clin Psychiatry. 1997; 58 Suppl 3:9-13; discussion 14-5.
    View in: PubMed
    Score: 0.010
  17. Treatment-emergent changes in sexual function with selective serotonin reuptake inhibitors as measured with the Rush Sexual Inventory. Psychopharmacol Bull. 1997; 33(4):755-60.
    View in: PubMed
    Score: 0.010
  18. Adjunctive Lanicemine (AZD6765) in Patients with Major Depressive Disorder and History of Inadequate Response to Antidepressants: A Randomized, Placebo-Controlled Study. Neuropsychopharmacology. 2017 Mar; 42(4):844-853.
    View in: PubMed
    Score: 0.010
  19. The effect of nefazodone on comorbid anxiety symptoms associated with depression: experience in family practice and psychiatric outpatient settings. J Clin Psychiatry. 1996; 57 Suppl 2:10-4.
    View in: PubMed
    Score: 0.010
  20. Association of obesity and inflammatory marker levels on treatment outcome: results from a double-blind, randomized study of adjunctive L-methylfolate calcium in patients with MDD who are inadequate responders to SSRIs. J Clin Psychiatry. 2015 Dec; 76(12):1635-41.
    View in: PubMed
    Score: 0.010
  21. The pro-inflammatory profile of depressed patients is (partly) related to obesity. J Psychiatr Res. 2015 Nov; 70:91-7.
    View in: PubMed
    Score: 0.010
  22. The efficacy of fluoxetine combined with a heterocyclic antidepressant in treatment-resistant depression: a retrospective analysis. J Clin Psychiatry. 1995 Aug; 56(8):338-43.
    View in: PubMed
    Score: 0.009
  23. A Randomized, Placebo-Controlled, Active-Reference, Double-Blind, Flexible-Dose Study of the Efficacy of Vortioxetine on Cognitive Function in Major Depressive Disorder. Neuropsychopharmacology. 2015 Jul; 40(8):2025-37.
    View in: PubMed
    Score: 0.009
  24. Effect of cognitive therapy with antidepressant medications vs antidepressants alone on the rate of recovery in major depressive disorder: a randomized clinical trial. JAMA Psychiatry. 2014 Oct; 71(10):1157-64.
    View in: PubMed
    Score: 0.009
  25. Effect of adjunctive L-methylfolate 15 mg among inadequate responders to SSRIs in depressed patients who were stratified by biomarker levels and genotype: results from a randomized clinical trial. J Clin Psychiatry. 2014 Aug; 75(8):855-63.
    View in: PubMed
    Score: 0.009
  26. Divalproex sodium in the treatment of refractory affective disorders. J Clin Psychiatry. 1993 Oct; 54(10):380-4.
    View in: PubMed
    Score: 0.008
  27. L-methylfolate as adjunctive therapy for SSRI-resistant major depression: results of two randomized, double-blind, parallel-sequential trials. Am J Psychiatry. 2012 Dec; 169(12):1267-74.
    View in: PubMed
    Score: 0.008
  28. A 12-week, randomized, double-blind, placebo-controlled, sequential parallel comparison trial of ziprasidone as monotherapy for major depressive disorder. J Clin Psychiatry. 2012 Dec; 73(12):1541-7.
    View in: PubMed
    Score: 0.008
  29. The role of serotonin in sexual dysfunction: fluoxetine-associated orgasm dysfunction. J Clin Psychiatry. 1991 Feb; 52(2):66-8.
    View in: PubMed
    Score: 0.007
  30. The use of referenced-EEG (rEEG) in assisting medication selection for the treatment of depression. J Psychiatr Res. 2011 Jan; 45(1):64-75.
    View in: PubMed
    Score: 0.007
  31. Psychosocial outcomes in patients with recurrent major depressive disorder during 2 years of maintenance treatment with venlafaxine extended release. J Affect Disord. 2010 Nov; 126(3):420-9.
    View in: PubMed
    Score: 0.007
  32. Assessing rates and predictors of tachyphylaxis during the prevention of recurrent episodes of depression with venlafaxine ER for two years (PREVENT) study. Psychopharmacol Bull. 2009; 42(3):5-20.
    View in: PubMed
    Score: 0.006
  33. The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) study: outcomes from the acute and continuation phases. Biol Psychiatry. 2007 Dec 15; 62(12):1371-9.
    View in: PubMed
    Score: 0.005
  34. The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) Study: Outcomes from the 2-year and combined maintenance phases. J Clin Psychiatry. 2007 Aug; 68(8):1246-56.
    View in: PubMed
    Score: 0.005
  35. Prevention of recurrent episodes of depression with venlafaxine ER in a 1-year maintenance phase from the PREVENT Study. J Clin Psychiatry. 2007 Jul; 68(7):1014-23.
    View in: PubMed
    Score: 0.005
  36. Paroxetine for prevention of depressive symptoms induced by interferon-alpha and ribavirin for hepatitis C. Aliment Pharmacol Ther. 2007 May 15; 25(10):1163-74.
    View in: PubMed
    Score: 0.005
  37. A randomized, double-blind, active-control study of sertraline versus venlafaxine XR in major depressive disorder. J Clin Psychiatry. 2006 Nov; 67(11):1674-81.
    View in: PubMed
    Score: 0.005
  38. High-dose sertraline strategy for nonresponders to acute treatment for obsessive-compulsive disorder: a multicenter double-blind trial. J Clin Psychiatry. 2006 Jan; 67(1):15-22.
    View in: PubMed
    Score: 0.005
  39. The Modified Rush Sexual Inventory: preliminary psychometric findings. Psychiatry Res. 2005 Dec 15; 137(3):175-81.
    View in: PubMed
    Score: 0.005
  40. A Double-blind, randomized trial of St John's wort, fluoxetine, and placebo in major depressive disorder. J Clin Psychopharmacol. 2005 Oct; 25(5):441-7.
    View in: PubMed
    Score: 0.005
  41. Vagus nerve stimulation for treatment-resistant depression: a randomized, controlled acute phase trial. Biol Psychiatry. 2005 Sep 01; 58(5):347-54.
    View in: PubMed
    Score: 0.005
  42. Randomized, placebo-controlled trial of nefazodone maintenance treatment in preventing recurrence in chronic depression. Biol Psychiatry. 2003 Oct 15; 54(8):806-17.
    View in: PubMed
    Score: 0.004
  43. Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of remission: a 47-week study. Am J Psychiatry. 2003 Jul; 160(7):1263-71.
    View in: PubMed
    Score: 0.004
  44. Lack of sexual dysfunction with the selective noradrenaline reuptake inhibitor reboxetine during treatment for major depressive disorder. Int Clin Psychopharmacol. 2003 May; 18(3):151-6.
    View in: PubMed
    Score: 0.004
  45. Divalproex sodium versus olanzapine in the treatment of acute mania in bipolar disorder: health-related quality of life and medical cost outcomes. J Clin Psychiatry. 2003 Mar; 64(3):288-94.
    View in: PubMed
    Score: 0.004
  46. Symptomatic and syndromal anxiety in chronic forms of major depression: effect of nefazodone, cognitive behavioral analysis system of psychotherapy, and their combination. J Clin Psychiatry. 2002 May; 63(5):434-41.
    View in: PubMed
    Score: 0.004
  47. Six-year perspectives on the safety and tolerability of nefazodone. J Clin Psychiatry. 2002; 63 Suppl 1:32-41.
    View in: PubMed
    Score: 0.004
  48. Efficacy and safety of mirtazapine in major depressive disorder patients after SSRI treatment failure: an open-label trial. J Clin Psychiatry. 2001 Jun; 62(6):413-20.
    View in: PubMed
    Score: 0.004
  49. Intramuscular ziprasidone, 2 mg versus 10 mg, in the short-term management of agitated psychotic patients. J Clin Psychiatry. 2001 Jan; 62(1):12-8.
    View in: PubMed
    Score: 0.003
  50. Multicenter double-blind comparison of sertraline and desipramine for concurrent obsessive-compulsive and major depressive disorders. Arch Gen Psychiatry. 2000 Jan; 57(1):76-82.
    View in: PubMed
    Score: 0.003
  51. Changes in weight during a 1-year trial of fluoxetine. Am J Psychiatry. 1999 Aug; 156(8):1170-6.
    View in: PubMed
    Score: 0.003
  52. Optimal length of continuation therapy in depression: a prospective assessment during long-term fluoxetine treatment. Am J Psychiatry. 1998 Sep; 155(9):1247-53.
    View in: PubMed
    Score: 0.003
  53. Mood disturbance versus other symptoms of depression in multiple sclerosis. J Int Neuropsychol Soc. 1995 May; 1(3):291-6.
    View in: PubMed
    Score: 0.002
  54. CNS stimulant potentiation of monoamine oxidase inhibitors in treatment-refractory depression. J Clin Psychopharmacol. 1991 Apr; 11(2):127-32.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.